We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

PPL:NYSEPPL Corporation Analysis

Data as of 2026-03-10 - not real-time

$38.27

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

PPL’s stock is trading above its 20‑day and 50‑day moving averages and near its 200‑day average, indicating a bullish price trend despite a MACD histogram that has turned negative and a bearish MACD signal. The RSI sits in the mid‑50s, suggesting neither overbought nor oversold conditions, while volatility has risen to roughly 20% over the past month and beta remains well below 1, pointing to modest systematic risk. The dividend yields close to 3% with a payout ratio near 68%, but free cash flow is negative, raising concerns about dividend sustainability. Valuation metrics show a trailing P/E that exceeds the industry average and a DCF‑derived fair value far below the current market price, implying the stock is overvalued. Recent earnings missed consensus expectations by a narrow margin, yet Barclays upgraded the stock to overweight and lifted its price target, citing a constructive outlook for the Pennsylvania rate case. The company also unveiled a $23 billion capital investment plan focused on grid modernization and clean energy, alongside a new equity offering that could fund growth but may dilute existing shareholders.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price above short‑term moving averages but bearish MACD signal
  • Recent earnings miss and upcoming equity dilution
  • Elevated volatility relative to typical utility stocks

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Barclays upgrade and higher price target
  • $23 billion capital plan aimed at modernizing the grid
  • Favorable Pennsylvania rate case outlook

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Stable regulated business model with attractive dividend yield
  • High leverage and negative free cash flow raising sustainability concerns
  • Overvaluation relative to DCF fair value

Key Metrics & Analysis

Financial Health

Revenue Growth2.80%
Profit Margin13.06%
P/E Ratio24.1
ROE8.16%
ROA3.09%
Debt/Equity131.15
P/B Ratio1.9
Op. Cash Flow$2.6B
Free Cash Flow$-1334375040
Industry P/E20.9

Technical Analysis

TrendBullish
RSI57.8
Support$35.60
Resistance$39.09
MA 20$37.76
MA 50$36.51
MA 200$35.89
MACDBearish
VolumeDecreasing
Fear & Greed Index81.18

Valuation

Fair Value$13.70
Target Price$40.67
Upside/Downside6.28%
GradeOvervalued
TypeValue
Dividend Yield2.98%

Risk Assessment

Beta0.18
Volatility19.53%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.